TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Perineural Injection Therapy in Patients With Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 20-85 year-old.~* Diagnosis was confirmed using an electrophysiological study and ultrasonography~Exclusion Criteria:~Cancer~* Coagulopathy~* Pregnancy~* Inflammation status~* Cervical radiculopathy~* Polyneuropathy, brachial plexopathy~* Thoracic outlet syndrome~* Previously undergone wrist surgery or steroid injection for CTS

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Perineural injection with 5% dextrose (Type: EXPERIMENTAL): Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
- Perineural injection with normal saline (Type: PLACEBO_COMPARATOR): Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Participants with a relapsing form of multiple sclerosis (RMS) having signed written informed consent.~Exclusion criteria:~* According to local labelling,~* Less than 18 years of age,~* Current or history of receiving teriflunomide,~* Previous treatment with leflunomide within 6 months prior to baseline,~* Participants with preexisting acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than 2 times the upper limit of normal (ULN),~* Known history of active tuberculosis (TB) or latent TB infection, either diagnosed by standard medical practice or guidelines (including skin or blood test, chest X-ray, or as appropriate per local practice),~* Known history of severe immunodeficiency, acquired immunodeficiency syndrome (AIDS), bone marrow disease, acute or severe active infections,~* Women who were pregnant or breast-feeding,~* Female participants with a positive pregnancy test at screening or women of child-bearing potential who did not agree to use reliable contraception throughout the course of the study,~* Male participants (only when required according to local labeling): unwilling to use reliable contraception during the course of the study,~* Additional exclusion criteria applicable for Europe (EU) countries (in accordance with contraindications of EU summary of product characteristics \[SmPC\]):~  * Participants with significantly impaired bone marrow function or significant anaemia, leukopenia, neutropenia or thrombocytopenia,~ * Participants with severe active infection until resolution,~ * Participants with severe renal impairment undergoing dialysis, because insufficient clinical experience was available in this participant group,~ * Participants with severe hypoproteinaemia, e.g. in nephrotic syndrome.~* Hypersensitivity to the active substance or to any of the excipients,~* Other additional contraindications per local labeling.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriflunomide (Type: EXPERIMENTAL): Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Canadian Pradaxa Acute Stroke Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients will be ≥ 18 years of age.~2. Minor ischemic stroke, defined as NIHSS score ≤ 3. Transient Ischemic Attack (TIA), defined as acute focal neurological deficits, with complete resolution of symptoms within 24 h of onset. In cases where onset time cannot be established, it will be considered to be the time when the patient was last known to be well.~3. Atrial Fibrillation (AF, paroxysmal or persistent). AF must be confirmed with ECG/Holter monitor, or by history All patients prescribed dabigatran according to the Canadian product label by the treating physician following their stroke/TIA. The decision to treat with dabigatran and the timing of the first dose will be determined by the attending physician, independent of the registry. All patients will have a CT scan or MRI, with findings consistent with an ischemic etiology of symptoms.~4. Ability to obtain informed consent obtained from patient or legally authorized representative.~Exclusion Criteria:~1. Acute or chronic renal failure, defined as eGFR \<30 ml/min (Cockcroft Gault formula).~2. Known hypersensitivity to dabigatran or any other contraindication to dabigatran therapy, as per Canadian label information.~3. Prior treatment with dabigatran or any other novel oral anticoagulant (including all Factor Xa antagonists). Treatment with warfarin prior to the stroke/TIA is acceptable, but enrolment cannot begin until the INR is ≤1.5.~4. Prior symptomatic ischemic stroke (TIA is not an exclusion criterion)~5. Any significant ongoing systemic bleeding risk, i.e. active GI/GU bleeding or recent major surgery.~6. Clinically significant recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of each Investigator.~7. Hereditary or acquired hemorrhagic diathesis.~8. Anticipated inability to comply with follow up.~9. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ranolazine and Exercise on Daily Physical Activity Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented CAD diagnosis~* Stable angina ≥ 3 months~Exclusion Criteria:~* Class III or IV heart failure~* Myocardial Infarction or coronary revascularization procedure within 2 months~* QT interval \> 500ms or prescribed medication known to prolong the QTc interval~* Contraindicated Medications~* Metformin dose \> 1700mg/day~* Class Ia, Ic and III anti-arrhythmics~* CYP3A inhibitors~* Simvastatin \>20mg/day~* Severe renal disease (\< 30ml/min creatinine clearance)~* Currently on dialysis~* Lack of transportation to the exercise and testing facilities~* Implanted pacemaker that is not rate responsive

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine plus Exercise (Type: ACTIVE_COMPARATOR): Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
- Placebo plus Exercise (Type: PLACEBO_COMPARATOR): Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of Warfarin Induction and Inhibition

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be 18-60 years old.~* Women of child bearing age must be willing to use measures to avoid conception during the study period.~* Subjects must agree not to take any known substrates, inhibitors, inducers or activators of either CYP2C9 or CYP3A4 from 1 week prior to the start of each study through the last day of study.~Exclusion Criteria:~* Current cigarette smoker~* Abnormal renal, liver function tests, physical exam, or recent history of hepatic, renal, gastrointestinal or neoplastic disease.~* Allergy to warfarin, fluconazole or rifampin and other chemically related drugs.~* Recent ingestion (\< 1 week) of any medication known to be metabolized by or alter CYP2C9 or CYP3A4 activity.~* A positive pregnancy test at the time of the pharmacokinetic study.~* Lab tests indicative of abnormal blood clotting capacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CYP2C9*1/*1 Genotype (Type: OTHER): This genotype is considered the wild type genotype. Individuals with the CYP2C9\*1/\*1 genotype have two \*1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
- CYP2C9*1B/*1B Haplotype (Type: OTHER): Individuals with the CYP2C9\*1B/\*1B haplotype have two CYP2C9\*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
- CYP2C9*1/*3 Genotype (Type: OTHER): Individuals with the CYP2C9\*1/\*3 genotype have one \*1 allele and one \*3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
- CYP2C9*2/*3 Genotype (Type: OTHER): Individuals with the CYP2C9\*2/\*3 genotype have one \*2 and one \*3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
- CYP2C9*3/*3 Genotype (Type: OTHER): Individuals with the CYP2C9\*3/\*3 genotype have two \*3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have access to a participating site and are willing to be followed for the duration of the study~* Willing to receive HIV test results~* Able to understand and comply with study requirements~* In good general health~* Have neutralizing adenovirus antibody levels that are less than a 1:12 ratio~* Agree to use acceptable methods of contraception for at least 21 days prior to study start and for the duration of the study.~Exclusion Criteria:~* HIV infected~* Positive hepatitis B surface antigen~* Positive anti-hepatitis C virus antibodies~* Prior receipt of an HIV vaccine~* Immunosuppressive drugs within 168 days prior to first vaccination~* Have received donated blood within 120 days prior to first vaccination~* Have received immunoglobulin within 60 days of the first vaccination~* Live attenuated vaccines or investigational research agents within 30 days prior to first vaccination~* Subunit or killed vaccines within 14 days prior to first vaccination~* Current preventive or therapeutic anti-tuberculosis (TB) treatment~* Any medical, psychiatric, or social condition that would interfere with the study~* Any occupational or other responsibility that would interfere with the study~* Serious adverse reactions to vaccines~* Autoimmune disease~* Immunodeficiency~* Active syphilis infection. Participants who have been fully treated for syphilis over 6 months prior to study entry are not excluded.~* Asthma. Participants who have had completely resolved childhood asthma are not excluded.~* Diabetes mellitus type I or II. Participants who have had isolated gestational diabetes are not excluded.~* Thyroid disease or removal of the thyroid~* Blood vessel swelling within the last 3 years~* Uncontrolled hypertension~* Body mass index (BMI) of 40 or higher~* Bleeding disorder~* Cancer. Participants whose cancer has been removed and is unlikely to recur during the study are not excluded.~* Seizure disorder. Participants who have not required medication or had a seizure for 3 years prior to study entry are not excluded.~* Removal of the spleen or have a nonfunctioning spleen~* Psychiatric conditions that may interfere with the study~* Pregnancy, breastfeeding, or plan to become pregnant during the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of the Device Nit-Occlud® PDA-R

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical and echocardiographic compatibility with PDA without associated heart disease requiring surgical solution~* Minimum diameter of the PDA 2 to 8 mm~* Systolic pulmonary pressure measured during cardiac catheterization, not on pass 2/3 of the values of the systolic systemic pressure~* Weight higher than 10 kg, regardless of age~* Patients who were diagnosed and recruited during the period 2009 - 2010~* Patients with trisomy 21 also fulfill the previous criteria, the number of patients with T21 will not exceed 10% of the entire group of patients.~* letter of consent signed by parents or legal guardian~Relative Exclusion Criteria:~* Infections that occur during acute bacteremia, viremia, which can be treated~* Febrile syndrome~* Tooth decay~* Once the acute solved considering the patient's inclusion into the study~Exclusion Criteria:~* Pregnant women~* Pulmonary hypertension, increased to 2 / 3 of systemic pressure~* Eisenmenger syndrome~* Other associated heart disease, requiring surgical solution~* Immuno-compromised patients~* Pathology oncology~* Hematologic or coagulation disorders~* Allergy to contrast medium~* Atypical or calcified Ductus~* Parents or legal guardians who do not accept the risks of catheterization~* Parents or legal guardians and patients who do not accept to sign the letter of consent or who revoke the consent.~* Patients who participated in another clinical investigation during the last 3 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nit-Occlud PDA-R (Type: OTHER): Interventional, prospective clinical study, non randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult volunteers with a body mass index (ie, the relationship between a person's height and weight) between 18 and 30 kg/m2 (inclusive), and body weight not less than 50 kg~* Have normal blood pressure between 90 and 140 mmHg systolic and \<=90 mmHg diastolic~* Female volunteers must have a negative serum beta human chorionic gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test on the day before each treatment period~* Female volunteers must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if of childbearing potential and sexually active, be practicing an effective method of birth control before entry and throughout the study~* Male volunteers must agree to use an adequate contraception method as deemed appropriate by the investigator~Exclusion Criteria:~* Currently have, or have a history of clinically significant medical illness that the investigator considers should exclude the volunteer or that could interfere with the interpretation of the study results~* Have a history of drug or alcohol abuse within the past 1 year or a history of clinically significant allergies, especially known hypersensitivity or intolerance to milk products~* Have a history of smoking or use of nicotine-containing substances within the previous 2 months~* Have had major or traumatic surgery within 12 weeks before screening or preplanned surgery or procedures that would interfere with the conduct of the study~* known allergy to the study drug or any of the excipients of the formulation or known allergy to heparin or history of heparin-induced thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment sequence AEBDC (Type: EXPERIMENTAL): None
- Treatment sequence BACED (Type: EXPERIMENTAL): None
- Treatment sequence CBDAE (Type: EXPERIMENTAL): None
- Treatment sequence DCEBA (Type: EXPERIMENTAL): None
- Treatment sequence EDACB (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.~Exclusion Criteria:~* Subjects who have used bupropion (Zyban or Wellbutrin) previously.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Infusion for Adolescent Depression and Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~MDD Cohort:~* Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID)~* CDRS-R score \>40.~* Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.~Anxiety Cohort:~* Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID)~* ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders~* Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.~* Failure to achieve remission with previous CBT or subject declines current CBT therapy~Both cohorts:~* Stable psychiatric medications and doses for the month prior to enrollment. Subjects may continue to engage in any ongoing psychotherapy.~* Medically and neurologically healthy on the basis of physical examination and medical history.~* Parents able to provide written informed consent and adolescents must additionally provide assent.~Exclusion:~* Current inpatient hospitalization or active suicidal ideation requiring referral for inpatient hospitalization for safety.~* History of psychotic disorder or manic episode diagnosed by MINI-KID~* History of substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology.~* Pregnancy (urine pregnancy tests on the day of scans for menstruating girls).~* Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
- Midazolam (Type: EXPERIMENTAL): Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete